undamentalytics Newsletter
Sign in

Lakefront Biotherapeutics NV key statistics and ratios

In fiscal 2025, Lakefront Biotherapeutics NV had return on equity of 10.7%, an operating margin of 26.5%, debt equal to 0.0% of equity and a current ratio of 20.15. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Gross margin——————99.3%95.0%—87.4%97.3%
Operating margin−226.1%−8.9%−70.7%−16.9%44.2%−37.4%−73.2%−54.3%−36.8%−68.3%26.5%
Net margin−299.3%41.7%−91.0%−10.5%17.9%−63.9%−44.0%−90.4%88.3%26.9%28.9%
Free-cash-flow margin−305.1%181.4%−119.9%−54.9%381.6%−98.3%−238.1%−218.8%−177.2%−122.2%−24.4%
Return on equity−33.1%10.0%−13.0%−2.7%7.3%−10.7%−3.9%−8.1%7.9%2.6%10.7%
Return on assets−27.3%7.4%−9.7%−2.2%4.0%−5.0%−1.9%−4.2%4.6%1.8%8.8%
Asset turnover0.090.180.110.210.220.080.040.050.050.070.30
Current ratio5.179.706.986.0410.268.458.588.119.029.9720.15
Debt to equity0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Interest cover (operating income ÷ interest)n/mn/mn/mn/m—n/mn/mn/mn/mn/m—
Effective tax rate—0.4%——−0.1%—————−6.2%
R&D as % of revenue327.9%107.8%171.9%113.5%50.3%109.5%136.7%111.8%100.7%121.7%41.3%
Capital spending as % of revenue15.4%3.4%4.2%3.7%2.7%8.9%23.1%11.4%7.8%6.1%1.2%
Free cash flow ÷ net income—435.0%——>999%———−200.6%−454.6%−84.5%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 3 checks passed · December 31, 2025
What it owns · $4.0bn
Short-term assets $3.6bnLonger-term assets $384m
What it owes, and who funded it · $4.0bn
Short-term liabilities $179mLonger-term liabilities $21mShareholders' equity $3.8bn
  • Short-term assets cover short-term liabilities $3.6bn of assets due within a year against $179m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $3.6bn short-term assets against $21m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of $334m against $1m of interest.

From Lakefront Biotherapeutics NV's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: LKFT vs MDGLLKFT vs PTCTACAD vs LKFT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lakefront Biotherapeutics NV's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lakefront Biotherapeutics NV.